<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781857</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-Nr.2015-0607</org_study_id>
    <nct_id>NCT02781857</nct_id>
  </id_info>
  <brief_title>Mass Spectral Fingerprinting in Lung Cancer</brief_title>
  <official_title>Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To answer the question whether a disease specific profile of breath in patients with lung
      cancer can be detected by an untargeted metabolomic study using exhaled breath analysis by
      mass spectrometry.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of volatile organic compounds (VOCs) in the exhaled breath will be analysed using mass spectrometry</measure>
    <time_frame>1 day, single measurement</time_frame>
    <description>The primary outcome will be the lung cancer specific mass spectrometric profile of VOCs of exhaled breath analysis (markers of lung cancer in exhaled breath).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Group A: Concentration of volatile organic compounds (VOCs) in the exhaled breath will be analysed using mass spectrometry before and after lung cancer surgery</measure>
    <time_frame>Group A: 2 measurements on 2 different days; Day 1: 1. measurement (before surgery), Day 2: (6-12 weeks after surgery): 2. measurement</time_frame>
    <description>The acquired profiles of mass spectral VOCs before and after lung cancer surgery will be analysed for significant differences.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>60 patients with lung cancer</arm_group_label>
    <description>Group A: 30 patients with squamous cell carcinoma eligible for lung cancer surgery
Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 controls</arm_group_label>
    <description>60 controls (group C) matched for age, gender, smoking history and lung function testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>60 patients with lung cancer</arm_group_label>
    <arm_group_label>60 controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with lung cancer will be included according to the predefined inclusion and
        exclusion criteria.

        Healthy controls will be recruited from the general population by printed flyers, newspaper
        advertisements and personal communication.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed lung cancer based on cytological or histological analysis.

          -  Group A: squamous cell carcinoma amenable for surgical resection (up to TNM stage
             IIIa).

          -  Group B: any type of lung cancer (small-cell carcinoma, non-small-cell carcinoma) not
             amenable for surgical resection.

          -  Group C: healthy controls.

          -  Age between 18 and 85 years at study entry

        Exclusion Criteria:

          -  Another 'active' secondary malignant disease (e.g. breast cancer, colon carcinoma) in
             group A and B, presence of any active malignant disease in group C (based on personal
             information).

          -  Acute inflammatory disease (e.g. common cold) within the last 4 weeks.

          -  Any other chronic lung disease than chronic obstructive lung disease (COPD).

          -  Acute or chronic hepatic disease.

          -  Renal failure or renal replacement therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Kohler, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malcolm Kohler, Prof. MD</last_name>
    <phone>+41 44 255 38 28</phone>
    <email>malcolm.kohler@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Engler, PhD</last_name>
    <phone>+ 41 44 255 48 01</phone>
    <email>anna.engler@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Pneumology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm Kohler, Prof. MD</last_name>
      <phone>+41 44 255 38 28</phone>
      <email>malcolm.kohler@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Anna Engler, PhD</last_name>
      <phone>+41442554801</phone>
      <email>anna.engler@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Malcolm Kohler, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zenobi Renato, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Engler Anna, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martinez-Lozano Sinues Pablo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaugg Martin, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weder Walter, Prof. MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hillinger Sven, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franzen Daniel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exhaled Breath</keyword>
  <keyword>Mass Spectrometry</keyword>
  <keyword>Fingerprinting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

